Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis

Arthritis and Rheumatism

Volumn 62, Issue 9, 2010, Pages 2595-2604

  Herrick, Ariane L ^a   Cutolo, Maurizio ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTINUCLEAR ANTIBODY; BETA 2 MICROGLOBULIN; CENTROMERE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA TOPOISOMERASE ANTIBODY; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME ANTIBODY; ISOPROSTANE DERIVATIVE; NITRIC OXIDE; PROSTANOID; THROMBOXANE; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIBODY BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD FLOW VELOCITY; CAPILLAROSCOPY; CAPILLARY DENSITY; CYANOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; HUMAN; ISCHEMIA; LUNG ARTERY PRESSURE; MICROVASCULATURE; NAILFOLD VIDEOCAPILLAROSCOPY; NEOVASCULARIZATION (PATHOLOGY); PALLOR; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN ULCER; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; ULCER; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; VASOSPASM; VIDEORECORDING; CAPILLARY; COMPLICATION; DISEASE COURSE; MICROCIRCULATION; NAIL; PATHOLOGY; PATHOPHYSIOLOGY; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN; VASCULARIZATION;

CAPILLARIES; DISEASE PROGRESSION; HUMANS; MICROCIRCULATION; NAILS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN;

EID: 77956365423     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27543     Document Type: Review

References (82)

1. Allen EV, Brown GE. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 1932:183:187-200.
2. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.
3. Cutolo M, Grassi W, Matucci Cerinic M. Raynaud's phenomenon and the role of capillaroscopy [review]. Arthritis Rheum 2003;48:3023-30. (Pubitemid 37409311)
4. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001;357:2042-8.
5. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005;44:587-96.
6. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-33.
7. Anderson ME, Moore TL, Lunt M, Herrick AL. Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging: a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. Rheumatology (Oxford) 2004;43;986-91. (Pubitemid 39144445)
8. Smith PJ, Ferro CJ, McQueen DS, Webb DJ. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. Br J Clin Pharmacol 1999;47:507-13.
9. Yamamoto T, Katayama I, Nichioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998;25:314-7. (Pubitemid 28088261)
10. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999;189:273-8.
11. Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford) 2006;45:676-84. (Pubitemid 43985335)
12. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994:21:1268-76. (Pubitemid 24234664)
13. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007;9 Suppl 2:S2.
14. Pignone A, Rosso AD, Brosnihan KB, Perfetto F, Livi R, Fiori G, et al. Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 2007;66:1305-10.
15. Furspan PB, Chatterjee S, Freedman RR. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004;50:1578-85. (Pubitemid 38608080)
16. Flavahan NA. Regulation of vascular reactivity in scleroderma: new insights into Raynaud's phenomenon. Rheum Dis Clin North Am 2008;34:81-7.
17. Murray AK, Moore TL, King TA, Herrick AL. Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. Arthritis Rheum 2006;54:1952-60.
18. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975:4:351-68.
19. Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980;59:393-408.
20. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34:41-55.
21. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
22. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
23. Konttinen YT, Mackiewitz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D, et al. Vascular damage and lack of angiogenesis in systemic sclerosis skin. Clin Rheumatol 2003;22:196-202.
24. Kahaleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma: dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995;38:1-4.
25. Bailey SR, Mitra S, Flavahan S, Flavahan NA. Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2005;289:H243-50. (Pubitemid 40934106)
26. 2C- adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol 2007;293:H1955-61.
27. Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19:574-9.
28. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI. Von Willebrand factor, thrombomodulin, thromboxane, β-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996;55:122-7.
29. Fatini C, Mannini L, Sticchi E, Rogai V, Guiducci S, Conforti ML, et al. Hemorheologic profile in systemic sclerosis: role of NOS3 -786T>C and 894G>T polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. Arthritis Rheum 2006;54:2263-70. (Pubitemid 44055887)
30. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular diseases in patients with systemic sclerosis. Arthritis Rheum 2002;46:3312-6.
31. Susol E, MacGregor AJ, Barrett JH, Wilson H, Black C, Welsh K, et al. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon. Arthritis Rheum 2000;43:1641-6. (Pubitemid 30452486)
32. Agarwal SK, Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008;34:17-40; v.
33. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
34. LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
35. Matucci-Cerinic M, Allanore Y, Czirjak L, Tyndall A, Muller-Ladner U, Denton C, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community: it is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009;68:1377-80.
36. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998;158:595-600. (Pubitemid 28144816)
37. Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006;54:1974-81. (Pubitemid 43877947)
38. Bukhari M, Herrick AL, Moore T, Manning J, Jayson MI. Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996;35:1127-31. (Pubitemid 126719649)
39. Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998;135:S21-30.
40. Fishman AP. Pulmonary hypertension: beyond vasodilator therapy [editorial]. N Engl J Med 1998;338:321-2.
41. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999;221:312-25. (Pubitemid 29386018)
42. Aschwanden M, Daikeler T, Jaeger KA, Thalhammer C, Gratwohl A, Matucci-Cerinic M, et al. Rapid improvement of nailfold capillaroscopy after intense immunosuppression for systemic sclerosis and mixed connective tissue disease. Ann Rheum Dis 2008;67:1057-9.
43. Miniati I, Guiducci S, Conforti ML, Rogai V, Fiori G, Cinelli M, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis 2009;68:94-8.
44. Hudson M, Thombs B, Baron M, and the Canadian Scleroderma Research Group. Time to diagnosis in systemic sclerosis: is sex a factor? Arthritis Rheum 2009;61:274-8.
45. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum 1973;16:619-28.
46. Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol 2008;22:1093-108.
47. Carpentier P, Franco A, Beani JC, Reymond JL, Amblard P. [Value of periungual capillaroscopy in the early diagnosis of systemic scleroderma.] Ann Dermatol Venereol 1983;110:11-20. In French.
48. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000;27:155-60. (Pubitemid 30058643)
49. De Angelis R, Grassi W, Cutolo M. A growing need for capillaroscopy in rheumatology [review]. Arthritis Rheum 2009;61:405-10.
50. Grassi W, Medico PD, Izzo F, Cervini C. Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum 2001;30:397-402. (Pubitemid 32565325)
51. Sulli A, Secchi ME, Pizzorni C, Cutolo M. Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885-7. (Pubitemid 351829394)
52. Smith V, Pizzorni C, De Keyser F, Decuman S, Van Praet JT, Deschepper E, et al. Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis 2010;69:1092-6.
53. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
54. Cutolo M, Pizzorni C, Sulli A. Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al [letter]. Arthritis Rheum 2007;56:2102-3. (Pubitemid 47110417)
55. Valim V, Assis LS, Simoes MF, Trevisani VF, Pucinelli ML, Andrade LE. Correlation between serum E-selectin levels and panoramic nailfold capillaroscopy in systemic sclerosis. Braz J Med Biol Res 2004;37:1423-7. (Pubitemid 39200132)
56. Del Rosso A, Distler O, Milia AF, Emanueli C, Ibba-Manneschi L, Guiducci S, et al. Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement. Ann Rheum Dis 2005;64:382-7. (Pubitemid 40283047)
57. Sulli A, Soldano S, Pizzorni C, Montagna P, Secchi ME, Villaggio B, et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009;36:1235-9.
58. Soldano S, Montagna P, Villaggio B, Parodi A, Gianotti G, Sulli A, et al. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis 2009;68:599-602.
59. Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford) 2006;45:314-20. (Pubitemid 43372847)
60. Riccieri V, Germano V, Alessandri C, Vasile M, Ceccarelli F, Sciarra I, et al. More severe nailfold capillaroscopy findings and anti-endothelial cell antibodies: are they useful tools for prognostic use in systemic sclerosis? Clin Exp Rheumatol 2008;26:992-7.
61. Cutolo M, Pizzorni C, Tuccio M, Burroni A, Craviotto C, Basso M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004;43:719-26. (Pubitemid 38807428)
62. Caramaschi P, Canestrini S, Martinelli N, Volpe A, Pieropan S, Ferrari M, et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology (Oxford) 2007;46:1566-9. (Pubitemid 47500571)
63. Smith V, Pizzorni C, De Keyser F, Decuman S, Van Praet JT, Deschepper E, et al. Validation of the qualitative and semiquantitative assessment of the scleroderma spectrum patterns by nailfold videocapillaroscopy: preliminary results [abstract]. Arthritis Rheum. 2009;60 Suppl:S164-5.
64. Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther 2009;11:220-7.
65. Alivernini S, De Santis M, Tolusso B, Mannocci A, Bosello SL, Peluso G, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009;60:426-35.
66. Sebastiani M, Manfredi A, Colaci M, D'Amico R, Malagoli V, Giuggioli D, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum 2009;61:688-94.
67. Mugii N, Hasegawa M, Hamaguchi Y, Tanaka C, Kaji K, Komura K, et al. Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology (Oxford) 2009;48:696-703.
68. Ong YY, Nikoloutsopoulos T, Bond CP, Smith MD, Ahern MJ, Roberts-Thomson PJ. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998;16:81-6. (Pubitemid 29004827)
69. Bredemeier M, Xavier RM, Capobianco KG, Restelli VG, Rohde LE, Pinotti AF, et al. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol 2004;31:286-94. (Pubitemid 38160750)
70. Hofstee HM, Noordegraaf AV, Voskuyl AE, Dijkmans BA, Postmus PE, Smulders YM, et al. Nailfold capillary density is associated with the presence and severity of pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2009;68:191-5.
71. Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL. Computerised nailfold video capillaroscopy: a new tool for the assessment of Raynaud's phenomenon. J Rheumatol 2005;32:841-8. (Pubitemid 40676493)
72. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994:120:199-206. (Pubitemid 24980413)
73. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000;(2):CD000953.
74. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93.
75. Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007;56:3837-46.
76. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009;60:870-7.
77. Moore TL, Vail A, Herrick AL. Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. Rheumatology (Oxford) 2007;46:363-4.
78. Anders HJ, Sigl T, Schattenkirchner M. Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope. Ann Rheum Dis 2001;60:407-9. (Pubitemid 32242757)
79. Bergman R, Sharony L, Shapira D, Nahir MA, Balbir-Gurman A. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003;139:1027-30. (Pubitemid 36994828)
80. Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007;26:1268-74.
81. Moore TL, Roberts C, Murray AK, Helbling I, Herrick AL. Reliability of dermoscopy in the assessment of patients with Raynaud's phenomenon. Rheumatology (Oxford) 2010;49:542-7.
82. De Angelis R, Cutolo M, Salaffi F, Restrepo JP, Grassi W. Quantitative and qualitative assessment of one rheumatology trainee's experience with a self-teaching programme in videocapillaroscopy. Clin Exp Rheumatol 2009;27:651-3.